Open AccessID:2038 THE ROLE OF THE CASPASE FAMILY in PF4-INDUCED APOPTOSIS IN BREAST CANCER IN VIVO STUDY
Author(s) -
Tengku Ahmad Damitri Al-Astani Tengku Din
Publication year - 2017
Publication title -
biomedical research and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 1
ISSN - 2198-4093
DOI - 10.15419/bmrat.v4is.277
Subject(s) - in vivo , apoptosis , cancer research , angiogenesis , medicine , caspase , breast cancer , cancer , breast carcinoma , pathology , immunology , biology , programmed cell death , biochemistry , microbiology and biotechnology
Background: Apoptosis is critical to the development and homeostasis of metazoans. Apoptotic dysregulation leads to various human pathologies including cancer, autoimmune and neurodegenerative disorders. Caspases, sub-members of cysteine proteases, are the central components of apoptotic response. The ELR-negative chemokine platelet factor 4 (PF4) was initially identified as an antiangiogenic agent. It inhibits endothelial cell proliferation, migration and angiogenesis in in vitro and in vivo and was further proving in the in vivo models of human colon carcinoma and murine melanoma xenograft mouse. However, there are no studies (either in-vivo or ex-vivo) which have conclusively demonstrated and characterized the PF4 effects on inducing apoptosis in breast cancer setting and therefore, this becomes the study’s central objective.
Aim: This study aimed to investigate PF4's effects on the apoptosis regulation mediated by caspase -3, -6, -7, -8 and -9 in 1-methyl-1-nitrosourea-induced (MNU) invasive murine breast carcinoma model.
Methods: Breast carcinoma were induced in 60, 21-day-old female Sprague Dawley Rat (SDR) using 1-methyl-1-nitrosourea until its size reached 14.5±0.5 mm. The tumors were divided into two groups: Group 1 (control pre-treated, n=20 and post treated, n=20), and Group 2 (PF4, n=20). PF4 were administered through focal intralesional injections at 20 µg/lesion dosage. After 5 days of treatment, the SDRs were sacrificed. Subsequently the tumor specimens were prepared for haematoxylin and eosin staining. The expression of caspases family members (caspase-3,-6,-7,-8 and-9) were detected using immunohistochemistry. The specimens were morphologically examined and the cell counts with positive caspases expressions were recorded.
Results: There was a significant reduction of tumor size after PF4 treatment compared to the controls. PF4 demonstrated differential effects on downstream effector caspases; both upregulated caspase-3 and -6, and downregulated caspase-7 expression was observed compared to controls. PF4 exhibited significant effects on the three caspases-3, -6 and -7 (p <0.001, p=0.004 and p=0.024, respectively). PF4 had no effect on caspase-8 (p=0.067) and caspase-9 (p=0.061) expressions.
Conclusion: This study found that PF4 significantly reduced the tumor sizes in a short time (less than 3 days) and acts differentially on the caspase-mediated apoptosis pathways and on the downstream levels of the apoptotic machinery.